LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Home・Lista de Ações・Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Fechado

SetorSaúde

48.32 -1.55

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

47.67

Máximo

49.86

Indicadores-chave
By Trading Economics
Rendimento	36M -2.3M
Vendas	-3.9M 208M
P/E Médio do Setor	48.435 51.415
EPS	0.208
Margem de lucro	-1.104
Funcionários	778
EBITDA	-72M 19M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+27.8% upside

Dividendos
By Dow Jones
Próximos Ganhos	4 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	65M 2.9B
Abertura anterior	49.87
Fecho anterior	48.32

Sentimento de Notícias

By Acuity

58%

42%

256 / 345 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bearish Evidence

31.35 / 32.36 Suporte e Resistência

Supernus Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

17 de mai. de 2026, 23:53 UTC

Aquisições, Fusões, Aquisições de Empresas

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

15 de mai. de 2026, 22:47 UTC

Ações em Alta

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 de mai. de 2026, 22:16 UTC

Aquisições, Fusões, Aquisições de Empresas

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 de mai. de 2026, 22:00 UTC

Grandes Movimentos do Mercado

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 de mai. de 2026, 18:09 UTC

Grandes Movimentos do Mercado

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

17 de mai. de 2026, 23:50 UTC

Conversa de Mercado

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

17 de mai. de 2026, 23:43 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

17 de mai. de 2026, 23:43 UTC

Conversa de Mercado

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

17 de mai. de 2026, 23:36 UTC

Conversa de Mercado

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

17 de mai. de 2026, 23:07 UTC

Aquisições, Fusões, Aquisições de Empresas

UOB: Transactions Part of Group's Capital Reallocation Strategy

17 de mai. de 2026, 23:06 UTC

Aquisições, Fusões, Aquisições de Empresas

UOB: Share Sale Agreements Entered With Singland Properties

17 de mai. de 2026, 23:05 UTC

Aquisições, Fusões, Aquisições de Empresas

UOB: Divestments' Aggregate Consideration of S$299M in Cash

17 de mai. de 2026, 22:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Prudential PLC to Fund Stake Acquisition via Internal Resources

17 de mai. de 2026, 22:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Prudential PLC to Acquire Stake for $389 Million

17 de mai. de 2026, 22:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

16 de mai. de 2026, 16:27 UTC

Aquisições, Fusões, Aquisições de Empresas

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16 de mai. de 2026, 15:26 UTC

Aquisições, Fusões, Aquisições de Empresas

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

16 de mai. de 2026, 08:20 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

15 de mai. de 2026, 22:17 UTC

Aquisições, Fusões, Aquisições de Empresas

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 de mai. de 2026, 21:59 UTC

Aquisições, Fusões, Aquisições de Empresas

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 de mai. de 2026, 21:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 de mai. de 2026, 21:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 de mai. de 2026, 21:16 UTC

Conversa de Mercado

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

15 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

15 de mai. de 2026, 20:19 UTC

Ações em Alta

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 de mai. de 2026, 19:41 UTC

Aquisições, Fusões, Aquisições de Empresas

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 de mai. de 2026, 19:35 UTC

Conversa de Mercado

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 de mai. de 2026, 19:33 UTC

Conversa de Mercado

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 de mai. de 2026, 18:35 UTC

Ganhos

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Comparação entre Pares

Variação de preço

Supernus Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

27.8% parte superior

Previsão para 12 meses

Média 63.17 USD 27.8%

Máximo 66 USD

Mínimo 55 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Supernus Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

6 ratings

Comprar

Manter

Vender

Com base em 6 analistas que deram avaliações de ações para Supernus Pharmaceuticals Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

31.35 / 32.36Suporte e Resistência

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentimento

By Acuity

256 / 345 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.